Berkeley Lights, Inc. (BLI), the leader in digital cell biology, announced today that Harbour BioMed, a global biopharmaceutical company has acquired the Beacon® Optofluidic platform to implement accelerated workflows for single-cell screening and analysis.
“Harbour BioMed is pleased to integrate the Berkeley Lights Beacon platform to further advance our monoclonal antibody discovery technology platforms. This would further enable us to speed up discovery and development, including single cell screening and profiling.” said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed. “It is an exciting phase in the history of Harbour BioMed as we look to further enhance our drug development capabilities to address unmet medical needs in patients across the globe.”
The Beacon platform is uniquely designed to carefully and specifically isolate, monitor, and assay almost any cell type. When used for antibody discovery, the Beacon platform can isolate and identify antibody-producing B-cells in less than one day, eliminating weeks of work. Once individual target cells are identified, the cells can be exported for sequencing or cloning. Each cell is tracked so that the phenotype can be linked to the genotype. Harbour BioMed will be the first company in the Greater China region to equip and leverage the use of this pioneering technology.
“Berkeley Lights’ digital cell biology platform offers the diversity, applicability, and agility to meet the demands of today’s changing landscape of antibody discovery,” said Andy Last, Chief Commercial Officer at Berkeley Lights. “We are pleased to work with Harbour BioMed and have them join our growing list of companies incorporating the Beacon platform to accelerate drug discovery in the fast-growing antibody therapeutics market.”
